{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:40:16Z","timestamp":1768016416342,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.intimp.2015.11.020","type":"journal-article","created":{"date-parts":[[2015,11,21]],"date-time":"2015-11-21T15:46:31Z","timestamp":1448120791000},"page":"9-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Effects of mTOR and calcineurin inhibitors combined therapy in Epstein\u2013Barr virus positive and negative Burkitt lymphoma cells"],"prefix":"10.1016","volume":"30","author":[{"given":"Sylvia J.","family":"Wowro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina R.L.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2015.11.020_bb0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2015.11.020_bb0010","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","article-title":"Epstein\u2013Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy","volume":"11","author":"Nourse","year":"2011","journal-title":"American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons."},{"key":"10.1016\/j.intimp.2015.11.020_bb0015","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3109\/08880018.2013.798844","article-title":"Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients","volume":"30","author":"Wistinghausen","year":"2013","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0020","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/cncr.26001","article-title":"Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder","volume":"117","author":"Picarsic","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2015.11.020_bb0025","series-title":"Response-Adapted Sequential Immuno-Chemotherapy of Post-Transplant Lymphoproliferative Disorders in Pediatric Solid Organ Transplant Recipients: Results from the Prospective Ped-PTLD 2005 Trial","author":"Maecker-Kolhoff","year":"2014"},{"key":"10.1016\/j.intimp.2015.11.020_bb0030","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1634\/theoncologist.11-6-674","article-title":"Post-transplant lymphoproliferative disorders","volume":"11","author":"LaCasce","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2015.11.020_bb0035","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.healun.2010.01.013","article-title":"Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients","volume":"29","author":"Manlhiot","year":"2010","journal-title":"The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation"},{"key":"10.1016\/j.intimp.2015.11.020_bb0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1399-3046.2008.00969.x","article-title":"Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients","volume":"13","author":"Schubert","year":"2009","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.intimp.2015.11.020_bb0045","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3389\/fmicb.2014.00728","article-title":"Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus","volume":"5","author":"Navari","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0050","first-page":"1397","article-title":"Epstein\u2013Barr virus and Burkitt lymphoma","volume":"60","author":"Brady","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-12-0404","article-title":"The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence","volume":"3","author":"Wall","year":"2013","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.intimp.2015.11.020_bb0060","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/ajt.12328","article-title":"PI3Kdelta inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein\u2013Barr virus (EBV)+B cell lymphomas","volume":"13","author":"Furukawa","year":"2013","journal-title":"American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons."},{"key":"10.1016\/j.intimp.2015.11.020_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/labinvest.3700494","article-title":"Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders","volume":"87","author":"El-Salem","year":"2007","journal-title":"Laboratory Investigation; a Journal of Technical Methods and Pathology"},{"key":"10.1016\/j.intimp.2015.11.020_bb0070","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.transproceed.2010.07.006","article-title":"Clinical insights for cancer outcomes in renal transplant patients","volume":"42","author":"Alberu","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.intimp.2015.11.020_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.beha.2012.04.008","article-title":"Targeting mTOR in mantle cell lymphoma: current and future directions","volume":"25","author":"Smith","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2015.11.020_bb0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN."},{"key":"10.1016\/j.intimp.2015.11.020_bb0090","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.107.711911","article-title":"Cardiac allograft vasculopathy: recent developments","volume":"117","author":"Schmauss","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2015.11.020_bb0095","first-page":"93","article-title":"Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy","volume":"9","author":"Rivinius","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.intimp.2015.11.020_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.healun.2007.08.014","article-title":"Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation","volume":"27","author":"Zuckermann","year":"2008","journal-title":"The Journal of Heart and Lung Transplantation: The Official Publication of The International Society for Heart Transplantation"},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2015.11.020_bb0105","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ndt\/gfm088","article-title":"Post-transplant lymphoproliferative disorder \u2014 the potential of proliferation signal inhibitors","volume":"22","author":"Pascual","year":"2007","journal-title":"Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association \u2014 European Renal Association"},{"key":"10.1016\/j.intimp.2015.11.020_bb0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.intimp.2015.11.020_bb0115","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007890-200008270-00027","article-title":"Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus","volume":"70","author":"Khanna","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2015.11.020_bb0120","doi-asserted-by":"crossref","first-page":"150835","DOI":"10.1155\/2013\/150835","article-title":"Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?","volume":"2013","author":"Morscio","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2013.11.036","article-title":"Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?","volume":"171","author":"Gonzalez-Vilchez","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.TP.0000103740.98095.14","article-title":"Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure","volume":"77","author":"Groetzner","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2015.11.020_bb0135","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.intimp.2013.02.012","article-title":"Steroid withdrawal and reduction of cyclosporine A under mycophenolate mofetil after heart transplantation","volume":"15","author":"Faulhaber","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0140","doi-asserted-by":"crossref","unstructured":"Alberu J. Clinical insights for cancer outcomes in renal transplant patients. Transplant. Proc. 42:S36\u201340.","DOI":"10.1016\/j.transproceed.2010.07.006"},{"key":"10.1016\/j.intimp.2015.11.020_bb0145","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.transproceed.2008.10.015","article-title":"Minimizing the risk of posttransplant malignancy","volume":"40","author":"Campistol","year":"2008","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.intimp.2015.11.020_bb0150","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ijc.22372","article-title":"C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma","volume":"120","author":"Schlee","year":"2007","journal-title":"International Journal of Cancer Journal International du Cancer"},{"key":"10.1016\/j.intimp.2015.11.020_bb0155","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1471-2407-13-250","article-title":"Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease \u2014 a combined tissue microarray, in vitro and in vivo study","volume":"13","author":"Mark","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2015.11.020_bb0160","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1309\/AJCPQYYE04AVGVYI","article-title":"Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation","volume":"138","author":"Nelson","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0165","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2015.11.020_bb0170","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11912-011-0187-7","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies","volume":"13","author":"Schatz","year":"2011","journal-title":"Current Oncology Reports"},{"key":"10.1016\/j.intimp.2015.11.020_bb0175","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0180","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.intimp.2015.11.020_bb0185","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","article-title":"The mTOR signalling pathway in human cancer","volume":"13","author":"Populo","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2015.11.020_bb0190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0195","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0952-7915(93)90135-F","article-title":"Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology","volume":"5","author":"Bierer","year":"1993","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cvr\/cvn079","article-title":"FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation","volume":"79","author":"Giordano","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.intimp.2015.11.020_bb0205","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1158\/0008-5472.CAN-07-6603","article-title":"Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer","volume":"68","author":"Basu","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2015.11.020_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023919","article-title":"Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40","volume":"6","author":"Basu","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2015.11.020_bb0215","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2012.02.004","article-title":"Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression","volume":"321","author":"Basu","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2015.11.020_bb0220","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1743-422X-10-314","article-title":"Comprehensive profiling of Epstein\u2013Barr virus-encoded miRNA species associated with specific latency types in tumor cells","volume":"10","author":"Yang","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2015.11.020_bb0225","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.semcancer.2013.07.005","article-title":"Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas","volume":"23","author":"Dolcetti","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0230","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bcp.2008.12.009","article-title":"Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12","volume":"77","author":"van Rossum","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2015.11.020_bb0235","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1097\/00007890-199712270-00039","article-title":"Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat","volume":"64","author":"Vu","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2015.11.020_bb0240","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.transproceed.2012.01.094","article-title":"Clinical experience of tacrolimus with everolimus in heart transplantation","volume":"44","author":"Wang","year":"2012","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.intimp.2015.11.020_bb0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/TP.0000000000000146","article-title":"Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions","volume":"98","author":"Piao","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2015.11.020_bb0250","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.healun.2013.08.005","article-title":"The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Heart Transplantation Report-2013; focus theme: age","volume":"32","author":"Dipchand","year":"2013","journal-title":"J. Heart Lung Transplant"},{"key":"10.1016\/j.intimp.2015.11.020_bb0255","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/TP.0b013e318277e344","article-title":"Characteristics of early and late PTLD development in pediatric solid organ transplant recipients","volume":"95","author":"Schober","year":"2013","journal-title":"Transplantation"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915301880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915301880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T15:45:10Z","timestamp":1567352710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915301880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":51,"alternative-id":["S1567576915301880"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.11.020","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of mTOR and calcineurin inhibitors combined therapy in Epstein\u2013Barr virus positive and negative Burkitt lymphoma cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}